Drug intelligence / Profile preview

Hupo Xiaoshi Granule

Development stage: Unknown
Lead developer: Shandong Wohua Pharmaceutical
Administration: Oral

Overview

Hupo Xiaoshi Granule (琥珀消石颗粒) is a traditional Chinese medicine (TCM) granule formulation developed and marketed by Shandong Wohua Pharmaceutical. It is specifically indicated for the treatment of urinary system stones, including kidney stones and urethral calculi, associated with damp-heat stasis syndrome. The drug works by promoting the expulsion of stones and addressing symptoms such as stone leaching and blood leaching (hematuria). It is available in both standard and sugar-free formulations, the latter being suitable for patients with dietary restrictions such as diabetes. As a TCM product, it consists of a complex mixture of herbal ingredients rather than a single active pharmaceutical ingredient.

Brand names: Hupo Xiaoshi Granule琥珀消石颗粒
Other names: Amber Xiaoshi Granules琥珀消石颗粒(无糖型)

Beyond the preview

Go deeper on Hupo Xiaoshi Granule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hupo Xiaoshi Granule.

Explore the full profile